Financials EOM Pharmaceuticals Holdings, Inc.
Equities
IMUC
US4525364026
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.21 USD | +40.00% | +14.13% | -9.48% |
Valuation
Fiscal Period: December | 2021 |
---|---|
Capitalization 1 | 20.69 |
Enterprise Value (EV) 1 | 22.02 |
P/E ratio | -3.82 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | - |
EV / FCF | -1,46,72,942 x |
FCF Yield | -0% |
Price to Book | -29.4 x |
Nbr of stocks (in thousands) | 49,271 |
Reference price 2 | 0.4200 |
Announcement Date | 24/06/22 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 |
---|---|---|
Net sales | - | - |
EBITDA | - | - |
EBIT 1 | -1.937 | -2.613 |
Operating Margin | - | - |
Earnings before Tax (EBT) 1 | -1.937 | -5.149 |
Net income 1 | -1.937 | -5.149 |
Net margin | - | - |
EPS 2 | -0.0387 | -0.1100 |
Free Cash Flow | - | -1.501 |
FCF margin | - | - |
FCF Conversion (EBITDA) | - | - |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 10/02/22 | 24/06/22 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 |
---|---|---|
Net Debt 1 | - | 1.33 |
Net Cash position 1 | 0.26 | - |
Leverage (Debt/EBITDA) | - | - |
Free Cash Flow | - | -1.5 |
ROE (net income / shareholders' equity) | - | 693% |
ROA (Net income/ Total Assets) | - | -169% |
Assets 1 | - | 3.047 |
Book Value Per Share 2 | 0 | -0.0100 |
Cash Flow per Share 2 | 0.0100 | 0.0100 |
Capex | - | - |
Capex / Sales | - | - |
Announcement Date | 10/02/22 | 24/06/22 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-9.48% | 23.79M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- IMUC Stock
- Financials EOM Pharmaceuticals Holdings, Inc.